Clinically validating target from disseminated cancer cells by determining whether status of target determined in cancer cells of individuals correlates with cancer-related information about clinical status of individuals

摘要

Method (I) for the clinical validation of a target from disseminated cancer cells, characterized in that for a population of individuals it is determined whether a status of the target determined in disseminated cancer cells of the individuals correlates with at least one cancer-related information about the clinical status of the individuals. Independent claims are also included for: (1) a method (II) for collecting a cancer-related data set (profile) of an individual, characterized in that: (a) the individual is examined for disseminated cancer cells; (b) optionally at least one aliquot of a sample derived from the body of the Individual examined in (a) is set aside in a substance library; (c) at least one cancer-related information about the clinical status of the individual is provided; and (d) the result obtained from the examination in (a) and the information provided in (c) and, optionally, the sample set aside in (b) are linked to each other; (2) a method (III) for the functional validation of clinically validated targets from disseminated cancer cells, characterized in that at least one active substance is allowed to act ex vivo upon target-carrying disseminated cancer cells, and the biological reaction of the cancer cells is determined; (3) a method (IV) for treating cancer in which the status of at least one validated target from disseminated cancer cells of an individual is determined and a therapy is chosen depending on the status; (4) a kit (V) for target-related cancer therapy, comprising: (a) agents for determining the status of at least one validated target in disseminated cancer cells of an individual; and (b) instructions for the therapy taking account of the determined status; (5) use of at least one agent suitable for chemotherapy and of at least one agent suitable for radiotherapy in the manufacture of a medicament for treating individuals having disseminated cancer cells expressing CK 20 mRNA; (6) use of at least one agent suitable for hormone therapy in the manufacture of a medicament for treating individuals having disseminated cancer cells expressing progesterone receptor mRNA; (7) use of at least one agent suitable for radiotherapy in the manufacture of a medicament for treating individuals having disseminated cancer cells over expressing bcl-2 mRNA; and (8) use of Herceptin in the manufacture of a medicament for treating individuals having disseminated cancer cells over expressing ErbB2 mRNA.